Industry Committee

This committee was established to 1) enhance membership and meeting participation by industry by creating networking and collaboration opportunities, particularly those involved with early stage clinical trials, 2) close the gap in the disconnect of meeting organizers/Society with what is happening in the biotech/pharma sector by providing input on opportunities to enhance the SITC meetings and 3) training assistance on Immuno-oncology.

Co-Chairs

Adrian Bot, MD, PhD
Kite Pharma, Inc.

Daniel S. Chen, MD, PhD
Genentech

Michelle Dawson, PhD
Bristol-Myers Squibb

Ramy Ibrahim, MD
AstraZeneca

Members

Sandra Aung, PhD
Nektar Therapeutics

Dirk Brockstedt, PhD
Aduro Biotech

Alessandra Cesano, MD, PhD
NanoString Inc.

David Chang, MD, PhD
Amgen

Roger Dansey
Merck & Co., Inc.

Peter Ellmark, PhD
Alligator Bioscience

Mark W. Frohlich, MD
Juno Therapeutics, Inc. 

Wael Harb, MD
Horizon BioAdvance

Kristen Hege, MD
Celgene Corporation 

Rachel W. Humphrey, MD
CytomX Therapeutics, Inc.

Karin U. Jooss, PhD
Pfizer

Harry M. Lander, PhD
TICA Group, LLC

James N. Lowder, MD
Pharmacyclics

Ira Mellman, PhD
Genentech 

Ewelina Morawa, MD
Novartis Oncology

Jospeh F. Murphy, PhD
Charles River Laboratories

Christian H. Poehlein, MD
Bayer Healthcare Oncology

Christophe Queva, PhD
Gilead Sciences

Julie Rubinstein, MBA
Adaptive Biotechnologies

Wenru Song, MD, PhD
AstraZeneca

Jon M. Wigginton, MD
MacroGenics, Inc.

Robert W. Wilkinson, PhD
MedImmune 

Benjamin J. Zeskind, PhD, MBA
Immuneering Corporation